Chinese TCM pharma company known for Compound Danshen Dripping Pills, a cardiovascular traditional-medicine product it has tried to get FDA-approved.
Chinese TCM pharma company known for Compound Danshen Dripping Pills, a cardiovascular traditional-medicine product it has tried to get FDA-approved.
Most income comes from one product family, sold mainly through hospitals, so inclusion on China's state insurance reimbursement list and the price it fetches matter a great deal. A Tianjin-based group, Tasly's parent, is the controlling shareholder.
Moat: narrow (brand, IP / patents). Long-standing branded TCM formula with clinical data supporting cardiovascular use.
Headquarters: Tianjin, China · Employees: 10,563
Size Tasly Pharmaceutical (600535.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $3.19B, the 757th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥14.36 on 18 Nov 2026.
Performance Over six months the shares fell 1.9%, against +1.3% for the median peer and -20.0% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue fell 4.2% over the last twelve months (peer median +25.3%); the operating margin is 18.9% (peer median 11.1%).
Valuation It trades at 16.7× forward earnings against a peer median of 22.1× (4th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is -10%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 8.9 points above its cost of capital (5.4% WACC).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥8.00B | CN¥8.15B | CN¥8.42B | CN¥8.59B | CN¥8.55B |
| Revenue growth | — | -3% | -2% | +1% | — |
| Gross profit | CN¥5.67B | CN¥5.25B | CN¥5.44B | CN¥5.53B | CN¥5.26B |
| EBITDA | n/a | CN¥1.82B | CN¥1.93B | CN¥1.96B | CN¥1.79B |
| Net income | CN¥1.22B | CN¥1.10B | CN¥956M | CN¥1.07B | -CN¥264M |
| Free cash flow | CN¥1.70B | CN¥1.09B | CN¥1.49B | CN¥1.94B | CN¥1.93B |
| Capital expenditure | CN¥350M | CN¥381M | CN¥565M | CN¥669M | CN¥404M |
| Total debt | CN¥284M | CN¥1.48B | CN¥1.85B | CN¥2.96B | CN¥2.47B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Tasly Pharmaceutical 600535.SS | $3.19B | -2% | -4% | 19% | 16.7× | -7.5% |
| Beijing TongRenTang 600085.SS | $4.91B | -12% | -17% | 8% | 28.7× | 1.7% |
| Yunnan Baiyao 000538.SZ | $15.0B | +11% | +5% | 11% | 18.3× | -0.2% |
| Shijiazhuang Yiling Pharmaceutical 002603.SZ | $3.83B | -7% | +32% | 21% | 17.5× | -3.9% |
| Shandong Buchang Pharmaceuticals 603858.SS | $2.25B | -7% | +4% | 10% | n/a | -2.5% |
| Jiangsu Kanion Pharmaceutical 600557.SS | $989M | -9% | +8% | 7% | 19.8× | 2.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600535.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.8% | -5.0% | 9th highest of 21 |
| 6-month return | -1.9% | +1.3% | 10th lowest of 21 |
| Distance from 52-week high | -11.6% | -29.6% | 7th highest of 21 |
| Revenue growth (TTM) | -4.2% | +25.3% | 4th lowest of 20 |
| Operating margin | 18.9% | 11.1% | 6th highest of 19 |
| Forward P/E | 16.7× | 22.1× | 4th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -7.5% | 4.7% | 2nd least demanding of 12 |
| Growth delivered (Del g) | -9.6% | +12.0% | lowest of 12 |
| Hurdle (Req g minus delivered) | +2.1 pp | -14.0 pp | 2nd most demanding of 12 |
| ROIC minus cost of capital | +8.9 pp | +5.7 pp | 8th highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tasly Pharmaceutical 600535.SS | China | $3.19B | -2% | -4% | 19% | 16.7× | -7.5% | -9.6% |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.13B | -25% | +136% | 29% | 36.1× | 17.7% | +98.4% |
| Legend Biotech Corp. Sponsored ADR LEGN | United States | $3.12B | -42% | +50% | 3% | 34.2× | n/a | n/a |
| China National Medicines 600511.SS | China | $3.26B | +3% | +3% | 4% | 10.5× | -10.0% | +5.4% |
| ACADIA Pharmaceuticals ACAD | United States | $3.08B | -15% | +15% | 10% | 17.8× | 9.2% | +19.4% |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.05B | -39% | +33% | 12% | 21.3× | 14.1% | +61.4% |
| Viking Therapeutics VKTX | United States | $3.34B | -9% | n/a | n/a | n/a | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.37B | +17% | -16% | 10% | 22.9× | 4.7% | +4.5% |
| Vericel VCEL | United States | $2.99B | +66% | +25% | 8% | 68.3× | 46.5% | +17.3% |
| Chengdu Kanghong Pharmaceutical 002773.SZ | China | $2.99B | -1% | -11% | 24% | 20.1× | -3.3% | +7.0% |
| Piramal Pharma PPLPHARMA.NS | India | $3.40B | +38% | +9% | 3% | 150.8× | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 13.5× | -3.4% | +10.6% |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | n/a | n/a | n/a |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |
| China Medical System 0867.HK | Hong Kong | $2.95B | -15% | +15% | 20% | 9.8× | 1.1% | +2.7% |
| Neuland Laboratories NEULANDLAB.NS | India | $2.95B | +28% | +50% | 26% | 63.4× | n/a | n/a |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 19.6× | -2.1% | +12.0% |
| Shanghai Junshi Biosciences 688180.SS | China | $3.48B | -31% | +29% | -15% | n/a | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 41.0× | 49.2% | +367.3% |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 63.6× | n/a | n/a |
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 16.8× | n/a | n/a |